Today: 19 May 2026
Browse Category

NYSE:KMB 22 October 2025 - 18 November 2025

Kenvue (KVUE) Stock Plunges Amid Tylenol and Talc Fears – What’s Next?

KVUE Stock Today (Nov. 18, 2025): Shares Slip as Appeals Court Weighs Tylenol Cases; Dividend Cleared; Kimberly‑Clark Deal Spread Persists

Kenvue shares traded near $16.13 midday, down 0.7%, after a U.S. appeals court signaled it may revive over 500 Tylenol-autism lawsuits. A Texas judge declined to block Kenvue’s $398 million dividend, which remains set for Nov. 26. The pending Kimberly-Clark deal implies $18.83 per share for KVUE, about 14% above its current price. Volume reached 21.1 million shares by 17:32 UTC.
Kenvue (NYSE: KVUE) Stock Surges on $40B Buyout – Spin‑Off Saga, Tylenol Turmoil & Investor Outlook

Kenvue (NYSE: KVUE) Stock Surges on $40B Buyout – Spin‑Off Saga, Tylenol Turmoil & Investor Outlook

Kimberly-Clark agreed to acquire Kenvue for $48.7 billion on Nov. 3, 2025, a 46% premium to its prior close. Kenvue shares surged nearly 20% on the news, while Kimberly-Clark stock dropped 13%. The deal follows a turbulent year for Kenvue, including a CEO ouster, falling sales, and litigation over Tylenol safety claims. Kenvue posted $15 billion in 2025 revenue and maintained gross margins near 59%.
Kenvue (KVUE) Stock Soars 20% on $48.7 B Buyout News – Q3 Earnings Beat and What’s Next

Kenvue (KVUE) Stock Soars 20% on $48.7 B Buyout News – Q3 Earnings Beat and What’s Next

Kimberly-Clark announced a $48.7 billion cash-and-stock deal to acquire Kenvue, sending Kenvue shares up about 20% in pre-market trading to near $17.50. Kenvue shareholders will receive $3.50 in cash and 0.14625 KMB shares per KVUE share. Kenvue reported Q3 net profit of $398 million, beating earnings expectations. Kimberly-Clark shares fell roughly 12.5% on the news.
Investors Beware: 7 Stocks to Avoid on October 22, 2025 Amid Alarming Warnings

Investors Beware: 7 Stocks to Avoid on October 22, 2025 Amid Alarming Warnings

Netflix shares fell over 6% after missing earnings due to a Brazilian tax charge. Texas Instruments warned of weak demand, pushing its stock down 7.6% and dragging chipmakers lower. Target neared multi-year lows as sales dropped and its CEO resigned. The Buffett Indicator hit 219%, with top bankers warning of overvalued markets and possible correction.

Stock Market Today

  • LeMaitre Q1 Performance Trails Surgical Equipment Sector Leaders
    May 19, 2026, 5:33 AM EDT. LeMaitre (NASDAQ:LMAT) reported Q1 revenue of $66.55 million, up 11.2% year-on-year but missed the mark relative to analyst estimates and offered weaker full-year guidance than peers. Despite beating earnings per share (EPS) estimates for the upcoming quarter, LMAT's stock fell 10%, trading at $100.83. In contrast, sector leader Intuitive Surgical (NASDAQ:ISRG) delivered a 23% revenue increase to $2.77 billion, surpassing expectations by 5.8%, driven by its robotic-assisted surgical systems business. The surgical equipment and consumables sector as a whole beat revenue estimates by 2.7% for Q1, with stocks rising an average of 6.4%. Industry growth is underpinned by aging populations and expanding use of AI and robotics, although challenges remain around R&D costs, regulatory compliance, pricing pressures, and potential supply chain issues.

Latest articles

Alphabet Approaches $5 Trillion With Google AI Cloud Move Targeting Nvidia

Alphabet Approaches $5 Trillion With Google AI Cloud Move Targeting Nvidia

19 May 2026
Alphabet shares rose in pre-market trading Tuesday after Google and Blackstone announced a U.S. AI cloud venture, with Blackstone committing $5 billion to add 500 megawatts of data-center capacity by 2027. Alphabet’s Class A shares closed Monday at $396.94 and were quoted at $401.09 before the market opened. The move coincides with the first day of Google I/O and follows strong Q1 earnings.
GeoVax Stock Rockets Nearly 80% as Tiny Vaccine Developer Grabs Biodefense Spotlight

GeoVax Stock Rockets Nearly 80% as Tiny Vaccine Developer Grabs Biodefense Spotlight

19 May 2026
GeoVax Labs shares surged nearly 80% to $2.21 Monday after announcing a $3 million private placement amid heightened interest in biodefense following a WHO emergency alert over Ebola in Africa. The company does not sell an approved Ebola vaccine; its lead candidate targets mpox and smallpox. GeoVax reported $1.3 million in cash at March 31 and a quarterly net loss of $5.3 million. The new funding is expected to close around May 19.
Evolution stock jumps on €2 billion move

Evolution stock jumps on €2 billion move

19 May 2026
Evolution AB shares surged 9% in Stockholm after the company announced a €2 billion share buyback, one of Sweden’s largest. The buyback starts immediately and may run until the 2027 annual meeting, capped at 10% of shares. The OMXS30 index rose just 0.75% in comparison. Evolution also secured a €300 million revolving credit facility from J.P. Morgan SE and Citibank Europe.

Popular

Vertiv shares slide ahead of AI data center update

Vertiv shares slide ahead of AI data center update

18 May 2026
Vertiv Holdings shares dropped 8.5% to $339.41 on Monday, erasing over $12 billion in market value ahead of a key investor conference. Trading volume reached about 7 million shares. The decline outpaced peers as U.S. tech stocks fell broadly. Vertiv urged shareholders to reject a mini-tender offer from Tutanota LLC for up to 500,000 shares.
Go toTop